

Announcement of executing license agreement with Thyas Co., Ltd.
(Granting the rights to development, manufacture, and sales for cancer immunotherapy with peptide vaccine for cancer therapy and iPS cell technology)

OncoTherapy Science, Inc. (President & CEO: Kyoko Fujiya; hereinafter, “OncoTherapy”) announces that OncoTherapy and Thyas Co., Ltd. (the headquarter located at Kyoto, Japan President : Yasumichi Hitoshi; hereinafter, “Thyas”) have agreed and executed the license agreement that OncoTherapy grants Thyas the exclusive rights to develop, manufacture and sell the regenerative T cell with peptide vaccine for cancer therapy.

(Agreement)

1. OncoTherapy grants Thyas the exclusive and worldwide rights to develop, manufacture and sell the specific cancer therapy peptide vaccine that OncoTherapy has the right of intellectual property for some specific cancers.
Furthermore, OncoTherapy shall cooperate and share with Thyas the necessary information on their development and manufacture.
2. Thyas aims at cancer therapy for patients with regenerative T cell manufactured utilizing the OncoTherapy’s cancer therapy peptide vaccine.
3. OncoTherapy will receive upfront payment, milestone payment as well as royalties from Thyas in accordance with the license agreement.

Thyas Co., Ltd. : <https://thyas.co.jp/>